Human Health Holdings Limited
Human Health Holdings Limited Fundamental Analysis
Human Health Holdings Limited (1419.HK) shows weak financial fundamentals with a PE ratio of 11.21, profit margin of 4.14%, and ROE of 3.54%. The company generates $0.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 43.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1419.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1419.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1419.HK trades at attractive valuation levels.
Growth Score
Moderate1419.HK shows steady but slowing expansion.
Financial Health Score
Excellent1419.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1419.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1419.HK Expensive or Cheap?
P/E Ratio
1419.HK trades at 11.21 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1419.HK's PEG of 1.89 indicates fair valuation.
Price to Book
The market values Human Health Holdings Limited at 0.40 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.75 times EBITDA. This signals the market has high growth expectations.
How Well Does 1419.HK Make Money?
Net Profit Margin
For every $100 in sales, Human Health Holdings Limited keeps $4.14 as profit after all expenses.
Operating Margin
Core operations generate 10.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.54 in profit for every $100 of shareholder equity.
ROA
Human Health Holdings Limited generates $2.64 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Human Health Holdings Limited produces operating cash flow of $68.45M, showing steady but balanced cash generation.
Free Cash Flow
Human Health Holdings Limited produces free cash flow of $66.03M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.17 in free cash annually.
FCF Yield
1419.HK converts 21.22% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.21
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.89
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.46
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.14
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How 1419.HK Stacks Against Its Sector Peers
| Metric | 1419.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.21 | 28.45 | Better (Cheaper) |
| ROE | 3.54% | 763.00% | Weak |
| Net Margin | 4.14% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.22 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.14 | 2795.60 | Strong Liquidity |
| ROA | 2.64% | -16588.00% (disorted) | Weak |
1419.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Human Health Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation